ID: h-4bc00f3610
Hypothesis
Thalamic anterior nucleus hyperconnectivity drives early-stage functional compensation that becomes pathological through adenosine-mediated metabolic vulnerability
We hypothesize that in early Alzheimer's disease (CDR 0.5-1), the anterior thalamic nuclei develop functional hyperconnectivity with hippocampal circuits as a compensatory response to entorhinal cortex degeneration, preserving episodic m.
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
We hypothesize that in early Alzheimer's disease (CDR 0.5-1), the anterior thalamic nuclei develop functional hyperconnectivity with hippocampal circuits as a compensatory response to entorhinal cortex degeneration, preserving episodic memory function. However, this hyperconnectivity creates a metabolically vulnerable state where increased neuronal activity elevates extracellular adenosine through ectonucleotidase pathways, suppressing synaptic efficacy and promoting amyloid-beta oligomerization at hyperconnected synapses. The transition from hyper-to hypo-connectivity marks a point of metabolic failure where compensatory mechanisms become pathological drivers.
...🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["ENTPD1 Expression<br/>Ectonucleotidase"]
B["Adenosine<br/>Neuromodulation"]
C["Metabolic Coupling<br/>Astrocyte-Neuron"]
D["Thalamic Hyperconnectivity<br/>Early Compensation"]
E["Adenosine-Mediated<br/>Metabolic Vulnerability"]
F["ENTPD1 as<br/>Adenosine Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
Minimal clinically important difference in Alzheimer's disease: Rapid review.
Supports
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3.
Supports
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Supports
Clinical progression on CDR-SB©: Progression-free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations.
Supports
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ENTPD1
No curated PDB or AlphaFold mapping for ENTPD1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for ENTPD1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ENTPD1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0857
Events (7d)
1
Price History
▲9.0%💾 Resource Usage
LLM Tokens
7,554
$0.0269
Total Cost
$0.0269
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF APP/PS1 mice receive chronic intracerebral microinjection of ENTPD1 inhibitor (polyoxometalate-1, 0.5μM, 4 weeks) or vehicle control starting at 3 months of age (pre-plaque stage), THEN ENTPD1 inhi | ≥50% increase in hippocampal extracellular adenosine; ≥40% increase in Aβ oligomer concentrations at thalamic-hippocampal synapses; ≥30% impairment in spatial m | — no observation — | pending | 0.68 |
| IF functional connectivity between anterior thalamic nuclei and hippocampal CA1 is measured using resting-state fMRI in early-stage Alzheimer's disease (CDR 0.5-1) versus cognitively normal controls, | Increased functional connectivity (Δ > 0.15 Fisher z-transformed correlation) between anterior thalamic nuclei and hippocampal CA1 in early AD; positive correla | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF functional connectivity between anterior thalamic nuclei and hippocampal CA1 is measured using resting-state fMRI in early-stage Alzheimer's disease (CDR 0.5-1) versus cognitively normal controls, THEN early AD subjects will exhibit significantly elevated bilateral anterior thalamic-hippocampal c
Predicted outcome: Increased functional connectivity (Δ > 0.15 Fisher z-transformed correlation) between anterior thalamic nuclei and hippocampal CA1 in early AD; positi
Falsification: Early AD subjects show equivalent or reduced anterior thalamic-hippocampal connectivity compared to controls; connectivity shows no correlation or negative correlation with memory performance; hyperco
pendingconf 68%
IF APP/PS1 mice receive chronic intracerebral microinjection of ENTPD1 inhibitor (polyoxometalate-1, 0.5μM, 4 weeks) or vehicle control starting at 3 months of age (pre-plaque stage), THEN ENTPD1 inhibition will elevate hippocampal extracellular adenosine by ≥50% (microdialysis HPLC), accelerate amy
Predicted outcome: ≥50% increase in hippocampal extracellular adenosine; ≥40% increase in Aβ oligomer concentrations at thalamic-hippocampal synapses; ≥30% impairment in
Falsification: ENTPD1 inhibition does not increase extracellular adenosine; amyloid burden remains unchanged or decreased; spatial memory performance is equivalent or improved in ENTPD1-inhibited mice; hyperconnecti
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.